BofA sees ‘particularly attractive entry point’ after Kenvue pullback

After Kenvue (KVUE) shares fell 9.3% on Friday after the WSJ reported that Health Secretary Robert F. Kennedy Jr. plans to release a report suggesting concerns linking Tylenol use in utero to the development of autism and ADHD, BofA analyst Anna Lizzul noted that the company’s new CEO and CFO took the opportunity in August to reset expectations at earnings and sees its lowered 2025 guidance as “achievable.” Given the current valuation discount to the average of HPC peers, the firm reiterates its Buy rating and $25 price target as it sees a widening discount offering “a particularly attractive entry point.”